ProKidney (PROK) investor relations material

Introduction and agenda

• ASN Kidney Week recap and corporate update covered rilparencel’s mechanism, CKD risks, and Q&A.

• PROACT 1 full enrollment is planned for Q1 2027, eGFR-slope topline data for Q2 2027, and confirmatory endpoint readout for 2H 2029.

KOL background and credentials

• Katherine R. Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington; she discussed residual CKD risk and rilparencel’s potential care role.

Market insights and analysis

• CKD affects 850 million people globally and ~1 in 7 people in the U.S.; global CKD deaths rose 41.5% from 1990 to 2017.

• Diabetes affects 589 million people worldwide in 2024 and accounts for half of CKD; diabetic kidney disease is linked to kidney failure, heart failure, cardiovascular disease, and death.

• More than 1 million U.S. patients with Stage 3b/4 CKD and diabetes are considered at high risk of kidney failure.

• High-risk patients may retain substantial kidney and cardiovascular risk despite expanded guideline-directed therapies; combination treatment may address multiple disease mechanisms.

• Tuttle’s modeling projected combination therapy could reduce kidney-failure risk by almost 60% and all-cause mortality by about one-third in diabetes with CKD; residual kidney-failure risk remains.